An observational study in Colorectal Cancer (Diagnosis), sponsored by University of Edinburgh. Recruiting at 2 sites in United Kingdom. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-28.
Sponsored by University of Edinburgh · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 388 studies in Colorectal Neoplasms with a site in United Kingdom — 72 open to participants now, 100 under way, 18 of them phase 3. Colorectal Neoplasms · United Kingdom.
Among the 388 studies in Colorectal Neoplasms with a site in United Kingdom, this one is the 2nd largest by planned enrollment of the 80 observational ones that give a count, is one of 9 that started in 2026, is one of 80 observational ones, reaches primary completion later than 52 of the 99 other live ones, and was the 382nd registered.
6,556 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.
Browse Colorectal Neoplasms studies →72 of the 388 studies in Colorectal Neoplasms with a site in United Kingdom are open now. Recruiting first, the newest first:
Imperial College London · Sites in United Kingdom
Ages 18+
Dr. Chris Gaffney · Sites in United Kingdom
Ages 60–85
University of Edinburgh · Sites in United Kingdom
Ages 18+
EMD Serono Research & Development Institute, Inc. · Sites in United Kingdom, United States, Argentina and 16 more countries
Ages 18+
Pierian Biosciences · Sites in United Kingdom
Ages 18+
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
388 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 94 · Phase 2 119 · Phase 3 77 · Phase 4 3
First in 1993; this study’s year is marked. 9 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 25,000 is above the median of 250 across 1,444 observational studies indexed under Colorectal Neoplasms.
Median enrollment 150 across the 299 interventional studies, 275 across the 80 observational. Of the 235 that completed or were terminated, 83 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
193 of 388 have an industry lead sponsor. The 10 most frequent:
University of Edinburgh is the lead sponsor of 403 studies on the registry; 64 are open to participants now.
University of Edinburgh has 8 studies filed under Colorectal Neoplasms — fewer than ten, so there is no comparison to draw.
24 of the studies in Colorectal Neoplasms with a site in United Kingdom that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04486378BioNTech SEA Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer | 2026-11 |
| NCT06607458Delcath Systems Inc.Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Colorectal Cancer w/Liver Dominant Disease | 2026-12 |
| NCT07151040One-carbon Therapeutics ABPhase 1/2 Study to Evaluate TH9619 in the Treatment of Advanced Solid Tumors | 2026-12 |
| NCT02222844Imperial College LondonImproving Radical Treatment Through MRI Evaluation of Pelvic Sigmoid Cancers | 2026-12 |
| NCT02246634Imperial College LondonScreening for Synchronous Metastases in Colorectal Cancer With DW-MRI (SERENADE) | 2026-12 |
Add all 24 to your calendar (.ics) → With an account.
Among the 388 studies in Colorectal Neoplasms with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Bowel cancer (colorectal cancer) is the 4th most common cancer in Scotland. Approximately 4,000 cases are diagnosed annually. Cancer-related deaths in Scotland are higher than other UK nations. Improving the early detection of bowel cancer, and therefore survival, is important.
The majority of bowel cancers are diagnosed within secondary-care (colorectal surgery unit). Upon GP referral to secondary-care, patients provide stool samples which are analysed for microscopic blood (FIT; faecal immunohistochemical test). Patients with a single positive result are more likely to have bowel cancer (0.2% risk if no blood detected, but 8.4% if detected). A positive test triggers further investigation, either CT scan or colonoscopy depending on the result. Currently, colonoscopy and radiology services throughout Scotland are under significant pressure causing delays.
Only 2% of patients referred to secondary-care are diagnosed with bowel cancer, and most colonoscopies performed do not yield significant findings. We have shown that performing two repeated FITs upon referral improves cancer pickup rate (sensitivity) and reduces missed cancers. We successfully implemented this in NHS Lothian and contributed to national guidelines.
This study will undertake a comprehensive retrospective review of the double-FIT urgent suspicion of bowel cancer pathway within NHS Lothian, from April 2022 (date of pathway inception) to August 2025, including around 25,000 patients that have been managed through the pathway. We will calculate key performance indicators and diagnostic accuracy of the pathway. Health economic analysis will determine cost-per-diagnosis. Risk factors for bowel cancer in this patient cohort will be identified to develop a support tool for primary and secondary-care. These results will be used to develop a future pathway to optimise pathway efficiency and cancer detection.
Design:
This is a retrospective observational cohort data-analysis study of patients managed within the NHS Lothian colorectal cancer (CRC) urgent suspicion of cancer (USoC) pathway and patients referred urgently to the Colorectal department from April 2022 to August 2025. April 2022 corresponds to the start of double FIT testing within the pathway. 5-year follow-up will be included (up to August 2030) to include 5-year cancer outcomes.
Methods:
Patients will be identified from our pathway. Estimated \~25,000 patients will be included. Data will be collected on patient characteristics, past medical and prescribing history, hospital presentations and investigation outcomes, cancer outcomes and mortality data. Linkage to relevant patient datasets will be required.
A service review of the USoC/urgent pathway will focus on key performance indicators such as time to diagnosis and treatment, as well as patient journey pathways (Sankey plots) and re-referral rates.
Furthermore, data will be analysed using standard methods such as odds-ratio multivariate logistic regression to determine any significant associations which enrich for CRC and significant bowel pathology in this patient group. Significant bowel pathology includes advanced adenoma, advanced colorectal neoplasia and inflammatory bowel disease (IBD). Importantly, the modelling will only utilise readily available information from the electronic health record (EHR) such as age, sex, blood haemoglobin, BMI and SIMD to improve pre-test probability by restricting the target population.
Markov models will be formed as part of the health economic analysis, and the financial cost per case detected within the pathway will be calculated. We will explore the impact of waiting times on disease progression and the associated impact on the financial costs of treatment and patient quality of life.
Results from the above analyses will be incorporated into a decision-flow as guidance for referrals to secondary-care.
Sample size calculation:
To perform regression analysis, at a significance level of 0.05, medium size effect and 10 predictors, 170 cases of CRC are required. Our database of \~25,000 patients has approximately 500 cases of CRC. There will be minimal anticipated drop-out. Therefore our required sample size will be achievable.22
Proposed analyses:
Standard summary statistics of the pathway will be reported (means, standard deviations, medians, inter-quartile range). Multivariate logistic regression will be performed to determine risk-factors significant for CRC at different FIT levels. Subgroup analyses will take place within different FIT result thresholds (\<10, 10-79, >79 µgHb/g) as well as between cancer and non-cancer patients, and for other significant bowel pathology. Long-term outcome data will be analysed, up to 5 years.
Furthermore, a service evaluation of the USoC/urgent pathway will focus on key performance indicators such as time to diagnosis and treatment, as well as patient journey pathways (Sankey plots) and re-referral rates. Markov models will be formed as part of the health economic analysis, and the financial cost per case detected within the pathway will be calculated. We will explore the impact of waiting times on disease progression and the associated impact on the financial costs of treatment and patient quality of life. The rate of interval cancers over long-term follow-up will be calculated.
We do not anticipate a significant amount of missing data. Data entries will be removed due to missing data on an analysis-by-analysis basis.
Adults referred to secondary-care with 'red-flag' gastrointestinal symptoms concerning for CRC.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients managed within the NHS Lothian CRC USoC/urgent pathway (including urgent referrals) due to 'red-flag' symptoms concerning of CRC from April 2022 to August 2025.
Exclusion Criteria:
Referred patients who did not return FIT
Referred patients who returned a single FIT
Diagnostic Test: Faecal Immunohistochemical test
Referred patients who returned two FITs
Diagnostic Test: Faecal Immunohistochemical test
Faecal Immunohistochemical test
Pathway diagnostic accuracy
Sensitivity, specificity, NNI of pathway
Time frame: 1 year
Cost per diagnosis
Cost per CRC diagnosis
Time frame: 1 year
Plan to share: No — There is no plan to share IPD due to patient numbers and confidentiality
Started May 2026 (actual). Primary completion is estimated for Aug 2027, 15 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.